

ClearView Managed Funds and Managed Investments

2024 Year end distribution

The following CFML Managed Funds and managed funds within the ClearView Managed Investments product have announced a distribution payment to all unitholders effective 30 June 2024.

Details of the distribution amount to be paid for each Fund are below:

| Fund name | APIR code | Final distribution (Cents Per Unit (CPU)) |
|--|-----------|---|
| CFML Managed Funds | | |
| CFML Fairlight Global Fund | CVW1586AU | 0.7138 |
| CFML First Sentier Investors Infrastructure Fund | NRM0036AU | 1.4341 |
| CFML ClearBridge RARE Emerging Markets Fund | NRM0038AU | 28.9009 |
| CFML Schroder Equity Opportunities Fund | NRM0028AU | 10.3308 |
| CFML Antipodes Global Fund | CVW1890AU | 8.4274 |
| CFML Money Market Fund | NRM0026AU | 5.4948 |
| ClearView Managed Investments | | |
| Aggressive 95 (formerly called Australian Shares Growth) | NRM0007AU | 1.7416 |

The distribution amount unitholders will receive is calculated by multiplying the above CPU by the number of units they held in each respective Fund as at 30 June 2024. The distribution amount is expected to be paid or reinvested (as specified by the investor) in the second half of July 2024.

The tax details for the distribution will be outlined in the tax statement to be sent to investors in the coming weeks, along with the tax details of any other distributions for the 2022/23 income tax year.

If you have any further queries about this distribution please contact the Service Centre on **132 977**, or speak with your Business Development Manager.

This notice has been prepared by ClearView Financial Management Limited ABN 99 067 544 549 AFSL 227677 (CFML). CFML is the responsible entity and issuer of the funds contained in this document. The information contained in this document is a summary and reference guide only and is based on CFML's interpretation of relevant Australian laws as at the date of publication. This information does not in any way constitute tax or legal advice and before relying on this information, you should seek independent expert advice. Please read the relevant Product Disclosure Statement (PDS) and consider the appropriateness of the information having regard to your objectives, financial situation or needs before making any decision about the relevant product(s). A copy of the latest PDS can be obtained by calling us on 132 977 or on our website humanfinancial.com.au/pds. Relevant, information about the Target Market Determination for this product is available at humanfinancial.com.au/tmd.

Information in this document is current as at the date of publication.